Amneal Pharmaceuticals’s bid to give a lift off to its Specialty business has suffered a setback, with the US Food and Drug Administration issuing a complete response letter for the firm’s IPX203 cardbidopa/levodopa extended-release candidate, a novel new drug application indicated for the treatment of Parkinson’s disease.
The New Jersey-based firm disclosed that the FDA’s letter rejecting its NDA in its current form indicated that an adequate...





